NCT05701306 - APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2027

Conditions

NeuroblastomaSolid Tumor

Interventions

DRUG

APG-115

Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.

DRUG

APG-2575

Orally once a day (QD) for 21 days, 21 days as a cycle.

Trial Locations (3)

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

RECRUITING

Tongji Hospital, Huazhong University of Science and Technology (HUST), Wuhan

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou